Non-Hodgkin's Lymphoma, Burkitt's Clinical Trial
Official title:
A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy
The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.
| Status | Recruiting |
| Enrollment | 90 |
| Est. completion date | September 2018 |
| Est. primary completion date | June 2018 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 19 Years to 81 Years |
| Eligibility |
Inclusion Criteria: 1. Age of = 18 (Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study during screening to rule out pregnancy. / A woman of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the last dose of tenofovir. / If the Investigator obtains information concerning the pregnancy of a female patient, the Investigator must terminate the study drug immediately in that patient, and report the information to IRB in the same manner as for SAE reporting) 2. CD 20 positive patients with Non-Hodgkin's lymphoma who are planned to receive anticancer treatment with rituximab based chemotherapy and A. ECOG performance status 0-2 B. Adequate renal function: serum creatinine level < 2 mg/dL (177 µmol/L) C. Adequate hematological function: hemoglobin = 9g/dL, absolute neutrophil count (ANC) = 1,500/µL, platelet count = 75,000/µL, unless abnormalities are due to bone marrow involvement by lymphoma D. Expected residual life = 6 months 3. Serum HBsAg negative, anti-HCV negative, but anti-HBc positive 4. ALT < 80IU/mL, serum bilirubin < 3.0mg/dL, unless abnormalities are due to liver involvement by lymphoma or tumor lysis syndrome 5. Individuals who were given and understood detailed explanations about this study, voluntarily decided to participate in the study, and provided written informed consent Exclusion Criteria: 1. Child-Pugh class C 2. Other chronic liver diseases such as autoimmune hepatitis or Wilson's disease 3. Patient who has hypersensitivity to study drug 4. Patient who has galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption 5. Patient who is pregnant or on lactating. Or who has plans for pregnant or lactation during study period even the partner of the male patient |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Seoul National University | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Seoul National University Hospital | Gilead Sciences, Konkuk University Hospital |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | HBV reactivation: defined as an increase in HBV DNA at least 10 folds from nadir or reappearance of HBsA or HBeAg in blood during treatment. | after 48 week from the End of treatment | No | |
| Secondary | Hepatitis flare: defined as elevation of HBV viral load more than 2,000IU/ml from the baseline or by the reappearance of HBsAg and elevation of ALT at least 100IU/ml from the baseline. | after 48 week from the End of treatment | No |